NASDAQ:OBSV - Obseva Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $18.18 +0.05 (+0.28 %) (As of 09/21/2018 04:00 PM ET)Previous Close$18.13Today's Range$18.00 - $19.4052-Week Range$7.17 - $20.35Volume159,219 shsAverage Volume79,906 shsMarket Capitalization$636.91 millionP/E Ratio-8.02Dividend YieldN/ABeta1.92 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland. Receive OBSV News and Ratings via Email Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OBSV CUSIPN/A Webwww.obseva.com Phone41-22-552-3840 Debt Debt-to-Equity RatioN/A Current Ratio14.23 Quick Ratio14.24 Price-To-Earnings Trailing P/E Ratio-8.02 Forward P/E Ratio-9.42 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.30 per share Price / Book5.51 Profitability EPS (Most Recent Fiscal Year)($2.25) Net Income$-66,920,000.00 Net MarginsN/A Return on Equity-59.29% Return on Assets-53.39% Miscellaneous Employees39 Outstanding Shares36,440,000Market Cap$636.91 million Obseva (NASDAQ:OBSV) Frequently Asked Questions What is Obseva's stock symbol? Obseva trades on the NASDAQ under the ticker symbol "OBSV." How were Obseva's earnings last quarter? Obseva SA (NASDAQ:OBSV) posted its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.05. View Obseva's Earnings History. When is Obseva's next earnings date? Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, November, 13th 2018. View Earnings Estimates for Obseva. What price target have analysts set for OBSV? 7 equities research analysts have issued twelve-month price targets for Obseva's shares. Their predictions range from $22.00 to $44.00. On average, they anticipate Obseva's stock price to reach $29.8571 in the next year. This suggests a possible upside of 64.4% from the stock's current price. View Analyst Price Targets for Obseva. What is the consensus analysts' recommendation for Obseva? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva. What are Wall Street analysts saying about Obseva stock? Here are some recent quotes from research analysts about Obseva stock: 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (8/1/2018) 2. HC Wainwright analysts commented, "We anticipate top-line data within the next few weeks from the Phase 2b EDELWEISS trial of OBE2109 (linzagolix), ObsEva’s main clinical-stage asset, in women with endometriosis. As a reminder, the broad goal of this study is the identification of two distinct therapeutic dosing options to serve the needs of the large and diverse endometriosis patient population: (1) a dosage with the potential for alleviating patient symptoms with moderate estrogen suppression that does not meaningfully decrease bone mineral density (BMD), thus obviating the need for hormonal add- back therapy (ABT); and (2), a higher dosage that fully or nearly fully suppresses estrogen, which would require ABT to restore estrogen with the purpose of counteracting bone loss." (6/11/2018) Who are some of Obseva's key competitors? Some companies that are related to Obseva include Reata Pharmaceuticals (RETA), Xencor (XNCR), Supernus Pharmaceuticals (SUPN), Opko Health (OPK), The Medicines (MDCO), Myokardia (MYOK), Mallinckrodt (MNK), Akcea Therapeutics (AKCA), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), Spectrum Pharmaceuticals (SPPI), AnaptysBio (ANAB), Global Blood Therapeutics (GBT), Pacira Pharmaceuticals (PCRX) and Cambrex (CBM). Who are Obseva's key executives? Obseva's management team includes the folowing people: Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 66)Mr. Timothy M. Adams, Chief Financial Officer (Age 58)Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 53)Mr. Mario Vincent Corso, Sr. Director of Investor RelationsDr. Elke Bestel, Chief Medical Officer & Head of Pharmacovigilance (Age 52) When did Obseva IPO? (OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. Has Obseva been receiving favorable news coverage? Media headlines about OBSV stock have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Obseva earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news headlines about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Obseva. Who are Obseva's major shareholders? Obseva's stock is owned by a number of of retail and institutional investors. Top institutional investors include VHCP Management II LLC (6.18%), FMR LLC (4.94%), First Manhattan Co. (4.14%), Vivo Capital LLC (2.54%), Acuta Capital Partners LLC (1.16%) and Point72 Asset Management L.P. (0.55%). Which institutional investors are buying Obseva stock? OBSV stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vivo Capital LLC, First Manhattan Co., Acuta Capital Partners LLC, Point72 Asset Management L.P., Millennium Management LLC, Laurion Capital Management LP and VHCP Management II LLC. How do I buy shares of Obseva? Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Obseva's stock price today? One share of OBSV stock can currently be purchased for approximately $18.16. How big of a company is Obseva? Obseva has a market capitalization of $636.91 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Obseva employs 39 workers across the globe. How can I contact Obseva? Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected] MarketBeat Community Rating for Obseva (NASDAQ OBSV)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 163 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 307MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?